CN112439012A - Health-care granules for preventing and treating diabetes, hyperglycemia and hypertension and preparation method thereof - Google Patents
Health-care granules for preventing and treating diabetes, hyperglycemia and hypertension and preparation method thereof Download PDFInfo
- Publication number
- CN112439012A CN112439012A CN201910801541.7A CN201910801541A CN112439012A CN 112439012 A CN112439012 A CN 112439012A CN 201910801541 A CN201910801541 A CN 201910801541A CN 112439012 A CN112439012 A CN 112439012A
- Authority
- CN
- China
- Prior art keywords
- hyperglycemia
- health
- preventing
- camellia seed
- treating diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 69
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 65
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000008187 granular material Substances 0.000 title claims description 42
- 240000001548 Camellia japonica Species 0.000 claims abstract description 102
- 235000018597 common camellia Nutrition 0.000 claims abstract description 102
- 229940064064 purslane extract Drugs 0.000 claims abstract description 50
- 239000000796 flavoring agent Substances 0.000 claims abstract description 33
- 239000000945 filler Substances 0.000 claims abstract description 30
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 30
- 239000000314 lubricant Substances 0.000 claims abstract description 30
- 239000002245 particle Substances 0.000 claims abstract description 28
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 238000007865 diluting Methods 0.000 claims abstract description 11
- 239000003085 diluting agent Substances 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 55
- 235000001855 Portulaca oleracea Nutrition 0.000 claims description 44
- 241000219304 Portulacaceae Species 0.000 claims description 44
- 241001122767 Theaceae Species 0.000 claims description 42
- 238000000605 extraction Methods 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 37
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 30
- 239000000706 filtrate Substances 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 27
- 239000008367 deionised water Substances 0.000 claims description 25
- 229910021641 deionized water Inorganic materials 0.000 claims description 25
- 239000003921 oil Substances 0.000 claims description 24
- 235000019198 oils Nutrition 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 21
- 108091005804 Peptidases Proteins 0.000 claims description 19
- 239000004365 Protease Substances 0.000 claims description 19
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 19
- 235000013399 edible fruits Nutrition 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 238000002791 soaking Methods 0.000 claims description 16
- 230000036541 health Effects 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 235000005593 Camellia sinensis f parvifolia Nutrition 0.000 claims description 12
- 244000041840 Camellia sinensis f. parvifolia Species 0.000 claims description 12
- 238000010790 dilution Methods 0.000 claims description 12
- 239000012895 dilution Substances 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 230000001804 emulsifying effect Effects 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 10
- 230000017854 proteolysis Effects 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 238000001694 spray drying Methods 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 238000009210 therapy by ultrasound Methods 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 9
- 238000007605 air drying Methods 0.000 claims description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 239000000811 xylitol Substances 0.000 claims description 7
- 235000010447 xylitol Nutrition 0.000 claims description 7
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 7
- 229960002675 xylitol Drugs 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 238000005238 degreasing Methods 0.000 claims description 5
- 230000001877 deodorizing effect Effects 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000010008 shearing Methods 0.000 claims description 5
- 239000002699 waste material Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 4
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 229960001462 sodium cyclamate Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 239000008280 blood Substances 0.000 abstract description 26
- 210000004369 blood Anatomy 0.000 abstract description 26
- 239000004480 active ingredient Substances 0.000 abstract description 12
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 230000003647 oxidation Effects 0.000 abstract description 7
- 238000007254 oxidation reaction Methods 0.000 abstract description 7
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 230000036737 immune function Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- 238000013329 compounding Methods 0.000 abstract description 2
- 230000007365 immunoregulation Effects 0.000 abstract description 2
- 241000526900 Camellia oleifera Species 0.000 description 20
- 230000037396 body weight Effects 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 9
- 229930182490 saponin Natural products 0.000 description 9
- 150000007949 saponins Chemical class 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 description 8
- 235000013824 polyphenols Nutrition 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 7
- 229960003105 metformin Drugs 0.000 description 7
- 238000007410 oral glucose tolerance test Methods 0.000 description 7
- 229940031439 squalene Drugs 0.000 description 7
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 6
- 108091005658 Basic proteases Proteins 0.000 description 6
- 108010059892 Cellulase Proteins 0.000 description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 6
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 6
- 229940106157 cellulase Drugs 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 239000004519 grease Substances 0.000 description 6
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 6
- 229960004488 linolenic acid Drugs 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000011732 tocopherol Substances 0.000 description 6
- 229930003799 tocopherol Natural products 0.000 description 6
- 235000010384 tocopherol Nutrition 0.000 description 6
- 229960001295 tocopherol Drugs 0.000 description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 235000021313 oleic acid Nutrition 0.000 description 5
- 229960002969 oleic acid Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000032683 aging Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000013118 diabetic mouse model Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 229920002488 Hemicellulose Polymers 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 108010059820 Polygalacturonase Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 239000010495 camellia oil Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000003467 diminishing effect Effects 0.000 description 3
- 108010093305 exopolygalacturonase Proteins 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- -1 flavonoid compounds Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000030136 gastric emptying Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- KVSNMTUIMXZPLU-UHFFFAOYSA-N D:A-friedo-oleanane Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(C)C1CCCC2C KVSNMTUIMXZPLU-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000519695 Ilex integra Species 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- JYYFMIOPGOFNPK-AGRJPVHOSA-N ethyl linolenate Chemical compound CCOC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC JYYFMIOPGOFNPK-AGRJPVHOSA-N 0.000 description 1
- 229940090028 ethyl linolenate Drugs 0.000 description 1
- JYYFMIOPGOFNPK-UHFFFAOYSA-N ethyl linolenate Natural products CCOC(=O)CCCCCCCC=CCC=CCC=CCC JYYFMIOPGOFNPK-UHFFFAOYSA-N 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Abstract
The invention discloses health-care particles for preventing and treating diabetes, hyperglycemia and hypertension and a preparation method thereof, wherein the health-care particles comprise the following raw materials in parts by weight: 20-80 parts of camellia seed kernel extract, 5-50 parts of purslane extract, 50-600 parts of diluting filler, 0.2-1 part of flavoring agent and 0.3-0.8 part of lubricant. The health-care particles for preventing and treating diabetes, hyperglycemia and hypertension are prepared by compounding the camellia seed kernel extract, the purslane extract, the diluent filler, the flavoring agent and the lubricant, have no toxic or side effect, no drug resistance, convenient eating and carrying and storage, have obvious immunoregulation effects of improving blood circulation, resisting oxidation, reducing blood sugar, reducing blood fat, enhancing immune function and the like, and various active ingredients play a role in synergy, so that the health-care particles have obvious effects of improving unsmooth blood circulation, reducing hyperglycemia and hyperlipidemia and the like, and are suitable for patients with hyperglycemia, hyperlipidemia and cardiovascular and cerebrovascular diseases.
Description
Technical Field
The invention relates to the technical field of health care products, in particular to health care particles for preventing and treating diabetes, hyperglycemia and hypertension and a preparation method thereof.
Background
The camellia seeds, also called camellia seeds, are one of four woody oil plants in the world, are mainly distributed in China and are unique oil resources in China. The camellia seeds are rich in 40-57% of unsaturated fatty acid, and the unsaturated fatty acid has higher oxidation resistance and better physiological activity. Besides a large amount of unsaturated fatty acids, the camellia seeds also contain various nutrient substances such as tea polyphenol, flavonoid compounds, squalene, tocopherol, tea saponin, camellia seed protein and the like. Tea polyphenol is a natural antioxidant, has obvious antioxidant effect, and can eliminate free radicals in the organism, so that the tea polyphenol has good curative effects in the aspects of radiation resistance, tumor prevention, neuroprotection and cardiovascular disease prevention and treatment; the flavonoid compound has pharmacological effects of improving microcirculation, changing in vivo enzyme activity, reducing blood lipid, reducing cholesterol, scavenging free radicals, resisting oxidation, inhibiting bacteria, resisting virus, resisting inflammation, and enhancing functions of face; the tea saponin has remarkable effects of relieving pain, relieving cough, resisting osmosis, removing speckle, diminishing inflammation, reducing cholesterol and resisting cancer; the squalene has effects of resisting anoxia, fatigue and aging, increasing oxygen utilization capacity of organism tissue, and improving symptoms and complications of diabetes, nephropathy, hypertension and heart disease; the camellia seed protein consists of 17 amino acids, wherein 7 amino acids such as threonine, phenylalanine, leucine, lysine, tryptophan, valine and isoleucine are necessary for human bodies. Modern pharmacological research shows that the camellia seed has the effects of regulating blood sugar and blood fat, resisting tumors, resisting inflammation, promoting penetration, resisting oxidation due to bacteriostasis, regulating immunologic function, protecting liver and the like.
Purslane, also known as purslane, wuxing grass, mochi, and the like. The purslane is a common traditional Chinese medicine, is mostly used as a medicine by using dry overground parts thereof, has sour and cold nature and taste, has the effects of clearing away heat and toxic materials, cooling blood and stopping bleeding and stopping dysentery, and is used for treating heat-toxin bloody dysentery, carbuncle and swelling, sore, eczema, erysipelas, snake and insect bites, hematochezia, hemorrhoidal bleeding and metrorrhagia and metrostaxis. The purslane contains various chemical components, mainly including organic acids, flavonoids, mushrooms, coumarins, alkaloids, volatile oil, polysaccharide and the like; modern pharmacological research shows that the active ingredients in the purslane have the effects of resisting bacteria, viruses and tumors, regulating blood fat, reducing blood sugar, resisting aging, resisting atherosclerosis and the like.
With the rapid development of social economy, the life rhythm and the aging process of people are accelerated, and symptoms such as low immunity, metabolic disturbance, physical fatigue, hypertension, hyperlipidemia, hyperglycemia and the like are expressed in different degrees on almost all adults, particularly the middle-aged and the elderly. The chief culprits of cardiovascular and cerebrovascular diseases, namely hypertension, hyperlipidemia and hyperglycemia, are serious harm to the health of modern people. The body with low immunity is easy to be infected or suffer from cancer, and the body can have harmful results due to high immunity, such as anaphylaxis, autoimmune diseases and the like. Therefore, there is a growing need for safer and healthier health foods that can regulate immunity, regulate body functions, prevent diseases, and promote health.
Based on the pharmacological individuality and common effect of camellia oleosa seeds and purslane in ancient books and modern authoritative books, the invention prepares the health-care particles capable of effectively preventing and treating diabetes, hyperglycemia and hypertension by reasonably matching the camellia oleosa seed extract and the purslane extract.
Disclosure of Invention
The invention aims to overcome the defects, provides the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension, has no toxic or side effect, no drug resistance, convenient eating, carrying and storage, has obvious immunoregulation effects of improving blood circulation, resisting oxidation, reducing blood sugar, reducing blood fat, enhancing immunologic function and the like, and has obvious effects of improving unsmooth blood circulation, reducing blood supply insufficiency, reducing hyperglycemia, hyperlipidemia and the like by various active ingredients through the synergistic interaction; in addition, the invention also provides a preparation method of the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension.
In order to achieve the purpose, the invention provides the following technical scheme:
the invention provides health-care granules for preventing and treating diabetes, hyperglycemia and hypertension, which comprise the following raw materials in parts by weight: 20-80 parts of camellia seed kernel extract, 5-50 parts of purslane extract, 50-600 parts of diluting filler, 0.2-1 part of flavoring agent and 0.3-0.8 part of lubricant.
The camellia seed kernel is fruit of camellia oleifera, and the camellia seed kernel extract is extracted from camellia seed kernel. The camellia seed kernel is rich in various nutrient substances such as tea polyphenol, squalene, oleic acid, linoleic acid, linolenic acid, tocopherol and the like, is easy to digest and absorb by human bodies, has the effects of reducing cholesterol, preventing and treating hypertension, cardiovascular diseases and diabetes, and also contains tea saponin and camellia seed protein, wherein the tea saponin is a nonionic surfactant with excellent performance and has physiological activities such as impermeability, inflammation resistance, pain resistance, cancer resistance and the like, and the camellia seed protein consists of 17 amino acids, wherein 7 amino acids such as threonine, phenylalanine, leucine, lysine, tryptophan, valine, isoleucine and the like are necessary for the human bodies.
The herba Portulacae extract is rich in ketones, epinephrine, polysaccharides, various vitamins, amino acids, and other compounds, has effects of clearing heat, diminishing inflammation, reducing blood lipid, reducing blood glucose, and resisting atherosclerosis, and can be used for preventing and treating hypertension, cardiovascular diseases, diabetes and liver injury diseases.
The health-care particles for preventing and treating diabetes, hyperglycemia and hypertension are prepared from the raw materials of the camellia seed kernel extract, the purslane extract, the diluent filler, the flavoring agent and the lubricant in a proper weight ratio, have the effects of resisting oxidation, resisting fatigue, enhancing immunity, reducing blood fat and blood sugar, tonifying qi and nourishing blood, tonifying spleen and nourishing stomach, promoting the secretion of saliva or body fluid and benefiting lung, preventing cancer and resisting aging and protecting liver, and have wide application prospects.
Preferably, the health-care particles for preventing and treating diabetes, hyperglycemia and hypertension comprise the following raw materials in parts by weight: 45 parts of camellia seed kernel extract, 20 parts of purslane extract, 89 parts of dilution filler, 0.5 part of flavoring agent and 0.4 part of lubricant.
The preparation method of the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension comprises the following steps:
(1) naturally airing or air-drying the mature oil tea fruits, and removing shells and seed shells to obtain oil tea seed kernels;
(2) drying the camellia seed kernels obtained in the step (1) in a dryer until the water content is 10-15%, and crushing to obtain crushed camellia seed kernels, wherein the particle size of the crushed camellia seed kernels is 20-30 meshes;
(3) sending the camellia seed kernels crushed in the step (2) into a squeezer and squeezing to obtain a crude camellia seed oil product and camellia seed kernel residues;
(4) placing the crude oil-tea camellia seed oil obtained in the step (3) into a plate-and-frame filter press for fine filtration, and degumming, deacidifying, dehydrating, decolorizing, deodorizing and degreasing the crude oil-tea camellia seed oil obtained in the step (3) in the plate-and-frame filter press to obtain refined oil-tea camellia seed oil;
(5) uniformly mixing the tea seed kernel dregs obtained in the step (3) with deionized water, adjusting the pH value to 8-11, adding protease for enzymolysis, wherein the enzymolysis reaction temperature is 45-55 ℃, performing enzymolysis reaction for 1-3 hours, performing centrifugal separation, sequentially obtaining an oil layer, an emulsion layer, a proteolysis liquid layer and a waste liquid layer from top to bottom, sucking layer by layer, and mixing the sucked oil layer and the proteolysis liquid layer to obtain a protein mixed solution;
(6) heating the protein mixed solution obtained in the step (5) to 49-53 ℃, preserving heat, stirring, adding the refined camellia oleosa seed oil obtained in the step (4), and uniformly stirring and mixing to obtain a solution A;
(7) and (4) transferring the solution A obtained in the step (6) into a high-speed shearing emulsifying machine, emulsifying at a high speed for 5-30 min, homogenizing for 2 times in a high-pressure homogenizer, and performing microwave sterilization to obtain the camellia seed kernel extract.
By adopting the technical scheme, the tea seed kernel extract is composed of tea seed oil and tea-oil camellia seed protein, active ingredients such as tea polyphenol, squalene, oleic acid, linoleic acid, linolenic acid, tocopherol, vitamin E, tea saponin and tea-oil camellia seed protein are retained to the greatest extent, and the quality of the tea seed kernel extract product is improved.
Preferably, the mass ratio of the tea seed kernel dregs, the deionized water and the protease in the step (5) is 1: 5-10: 0.8 to 2.2; the mass ratio of the refined camellia oleosa seed oil to the protein mixed liquor in the step (6) is 1: 2.5 to 4.
The preparation method of the health-care particle for preventing and treating diabetes, hyperglycemia and hypertension comprises the following steps:
a. taking whole purslane as a raw material, cleaning, washing and chopping the whole purslane, putting the cleaned, chopped and chopped whole purslane into an extraction tank, adding deionized water, carrying out ultrasonic treatment for 5-10 min under the conditions of frequency of 20-30 KHz and power of 400-600W, soaking for 1-3 hours, decocting for 2-6 hours at 80-95 ℃, and filtering to obtain a first filtrate and a first filter residue; wherein the weight ratio of the fresh purslane to the deionized water is 1: 2-6;
b. b, putting the first filter residue obtained in the step a into an extraction tank, adding deionized water, carrying out ultrasonic treatment for 5-10 min under the conditions that the frequency is 20-30 KHz and the power is 400-600W, soaking for 0.5-1 h, decocting for 2-4 h at 80-95 ℃, and filtering to obtain a second filtrate and a second filter residue;
c. and (c) combining the first filtrate obtained in the step a and the second filtrate obtained in the step b, and concentrating until the relative density is 1.05-11.10 (60 ℃), so as to obtain the purslane extract.
By adopting the technical scheme, the extraction efficiency of the purslane extract is high, and the purity of active substances such as linolenic acid, linoleic acid, 9, 12-ethyl octadecadienoate, ethyl linolenate, 4 alpha-methyl-3 beta-hydroxyl friedelane and the like in the purslane extract is higher.
Preferably, the diluent filler is any one or combination of more of lactose, mannitol, water-soluble starch and water-soluble cyclodextrin.
Preferably, the flavoring agent is any one or combination of more of aspartame, stevioside, xylitol and sodium cyclamate.
Preferably, the lubricant is any one or combination of more of magnesium stearate, stearic acid, zinc stearate, aerosil and talcum powder.
The second aspect of the invention provides a preparation method of the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension, which comprises the following steps:
s1, weighing the camellia seed kernel extract, the purslane extract, the dilution filler, the flavoring agent and the lubricant according to the formula amount;
s2, mixing the camellia seed kernel extract and the purslane extract weighed in the step S1, and mechanically stirring for 0.5-1.5 hours to obtain a mixture A; uniformly mixing the diluting filler, the flavoring agent and the lubricant weighed in the step S1 to obtain a mixture B;
s3, adding 50-80% ethanol into the mixture A obtained in the step S2, carrying out cold soaking extraction for 2-3 times, filtering, combining filtrates, and concentrating to obtain thick paste with the relative density of 1.3-1.35 (60 ℃);
s4, adding the mixture B obtained in the step S2 into the thick paste obtained in the step S3, uniformly stirring, spray drying, crushing, granulating, grading, and performing microwave sterilization to obtain the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension.
Preferably, the mass ratio of the mixture a to the ethanol in the step S3 is 1: 2-10; the spray drying conditions in step S4 are as follows: the air inlet temperature is 160 ℃, the air outlet temperature is 85 ℃, and the feeding temperature is 45 ℃.
By adopting the technical scheme, the method has the advantages that,
compared with the prior art, the invention has the beneficial effects that:
1. the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension are prepared by compounding the camellia seed kernel extract, the purslane extract, the diluting filler, the flavoring agent and the lubricant, have no toxic or side effect, no drug resistance, convenient eating, carrying and storage, obvious immune regulation effects of improving blood circulation, resisting oxidation, reducing blood sugar, reducing blood fat, enhancing immune function and the like, and various active ingredients play a role in synergy, so that the health-care granules have obvious effects of improving unsmooth blood circulation, reducing hyperglycemia and hyperlipidemia and the like, and are suitable for patients with hyperglycemia, hyperlipidemia and cardiovascular and cerebrovascular diseases.
2. The preparation method of the camellia seed kernel extract in the health-care particles for preventing and treating diabetes, hyperglycemia and hypertension is simple, the raw materials are easy to obtain, the effective ingredients in the camellia seed kernels are fully released through multiple times of extraction and filtration, and the yield of the extracted active ingredients is high; meanwhile, the preparation method of the purslane extract is simple, the raw materials are easy to obtain, the active ingredients of the purslane are retained to the maximum extent, the extraction rate is high, the moisture content is low, the raw material resources can be fully utilized, and the method is very suitable for industrial production.
3. The preparation method of the health-care particles for preventing and treating diabetes, hyperglycemia and hypertension, which is disclosed by the invention, is characterized in that the health-care particles for preventing and treating diabetes, hyperglycemia and hypertension are prepared by taking the camellia seed kernel extract, the purslane extract, the diluting filler, the flavoring agent and the lubricant as raw materials.
Drawings
FIG. 1 is a flow chart of a method for preparing a tea seed kernel extract according to the present invention.
FIG. 2 is a flow chart of the preparation method of purslane extract of the present invention.
Fig. 3 is a flow chart of a preparation method of the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension according to the present invention.
FIG. 4 is a graph showing the hypoglycemic effect of a type II diabetic mouse model after gavage with 150mg/Kg of the body weight of the health-care granules for prevention and treatment of diabetes, hyperglycemia and hypertension according to example 1 in an oral glucose tolerance test.
FIG. 5 is a graph showing the effect of lowering blood sugar in a type II diabetic mouse model after gavage with 150mg/Kg of the body weight of the health-care granule for prevention and treatment of diabetes, hyperglycemia and hypertension according to example 2 in an oral glucose tolerance test.
FIG. 6 is a graph showing the effect of lowering blood sugar in a type II diabetic mouse model after gavage with 150mg/Kg of the body weight of the health-care granule for prevention and treatment of diabetes, hyperglycemia and hypertension according to example 3 in an oral glucose tolerance test.
Detailed Description
In order to make the technical means, the characteristics, the purposes and the functions of the invention easy to understand, the invention is further described with reference to the specific drawings.
Example 1
A health-care particle for preventing and treating diabetes, hyperglycemia and hypertension comprises the following raw materials by weight: 21g of camellia seed kernel extract, 21g of purslane extract, 350g of dilution filler, 0.2g of flavoring agent and 0.35g of lubricant.
Referring to fig. 1, the preparation method of the camellia seed kernel extract in the present embodiment includes the following steps:
(1) naturally airing or air-drying the mature oil tea fruits, and removing shells and seed shells to obtain oil tea seed kernels;
(2) drying the camellia seed kernels obtained in the step (1) in a dryer until the water content is 12%, and crushing to obtain crushed camellia seed kernels, wherein the particle size of the crushed camellia seed kernels is 20-30 meshes;
(3) sending the camellia seed kernels crushed in the step (2) into a squeezer and squeezing to obtain a crude camellia seed oil product and camellia seed kernel residues;
(4) placing the crude oil-tea camellia seed oil obtained in the step (3) into a plate-and-frame filter press for fine filtration, and degumming, deacidifying, dehydrating, decolorizing, deodorizing and degreasing the crude oil-tea camellia seed oil obtained in the step (3) in the plate-and-frame filter press to obtain refined oil-tea camellia seed oil;
(5) uniformly mixing the tea seed kernel dregs obtained in the step (3) with deionized water, adjusting the pH value to 8-11, adding protease for enzymolysis, wherein the enzymolysis reaction temperature is 45-55 ℃, performing enzymolysis reaction for 1-3 hours, performing centrifugal separation, sequentially obtaining an oil layer, an emulsion layer, a proteolysis liquid layer and a waste liquid layer from top to bottom, sucking layer by layer, and mixing the sucked oil layer and the proteolysis liquid layer to obtain a protein mixed solution; wherein the mass ratio of the tea seed kernel dregs, the deionized water and the protease is 1: 8: 0.85; wherein the protease is alkaline protease;
(6) heating the protein mixed solution obtained in the step (5) to 50 ℃, preserving heat, stirring, adding the refined camellia oleosa seed oil obtained in the step (4), and uniformly stirring and mixing to obtain a solution A; wherein the mass ratio of the refined camellia oleosa seed oil to the protein mixed liquor is 1: 3;
(7) and (4) transferring the solution A obtained in the step (6) into a high-speed shearing emulsifying machine, emulsifying at a high speed for 10min, homogenizing for 2 times in a high-pressure homogenizer, and sterilizing by microwave to obtain the camellia seed kernel extract.
The protease in the embodiment adopts alkaline protease to destroy the cell structure to release the grease, and compared with the grease enzymolyzed by single cellulase or pectinase, the yield is higher, the solubility of a protein system is improved, and the protein content can reach 45%; in addition, through the enzymolysis of protease, protein exists in the form of polypeptide, and is more easily absorbed by human body.
The camellia oleifera fruit stacked for 5-10 years in the embodiment can be adopted as the camellia oleifera fruit, the post-ripening of the camellia oleifera fruit can be promoted and natural fermentation can be carried out simultaneously in the natural air drying process by stacking, part of starch in the camellia oleifera fruit is degraded into carbohydrate with simpler structures such as soluble sugar and the like in the natural fermentation process, the protein is degraded to generate small molecular weight protein, polypeptide and amino acid with higher nutritional value, and the cellulose substance is further degraded under the action of cellulase, so that the extraction speed of the camellia oleifera seed kernel extract is accelerated, the extraction rate is higher, the content of active ingredients in the camellia oleifera seed kernel extract is greatly improved, and the nutritional value is higher.
Referring to fig. 2, the preparation method of the purslane extract in the present embodiment includes the following steps:
a. cleaning, cleaning and chopping purslane whole plant as a raw material, putting the purslane whole plant into an extraction tank, adding deionized water, carrying out ultrasonic treatment for 10min under the conditions of frequency of 30KHz and power of 550W, soaking for 1 hour, decocting for 2.5 hours at 80-95 ℃, and filtering to obtain a first filtrate and a first filter residue; wherein the weight ratio of the fresh purslane to the deionized water is 1: 5;
b. b, putting the first filter residue obtained in the step a into an extraction tank, adding deionized water, carrying out ultrasonic treatment for 10min under the conditions of frequency of 30KHz and power of 550W, soaking for 0.5 h, decocting for 2 h at 80-95 ℃, and filtering to obtain a second filtrate and second filter residue;
c. and (c) combining the first filtrate obtained in the step a and the second filtrate obtained in the step b, and concentrating until the relative density is 1.05-11.10 (60 ℃), so as to obtain the purslane extract.
The purslane whole plant in the embodiment can be the purslane whole plant stacked for 5-10 years, the purslane can be naturally fermented while being naturally air-dried in the stacking process, the unique flavor of the purslane is kept in the natural fermentation process, the bitter taste in the purslane can be thoroughly removed, and meanwhile, the components such as cellulose and hemicellulose which are difficult to absorb and convert by a human body in the purslane are decomposed into small molecular components which can be absorbed by the human body, so that the extraction speed of the purslane extract is higher, the extraction rate is higher, the content of active components in the purslane extract is greatly improved, and the active components in the purslane extract are easier to absorb and digest by the human body.
The diluent filler in this example is a water-soluble starch
The flavoring agent in this example is xylitol.
The lubricant in this example is magnesium stearate, which has good flow properties.
In the embodiment, water-soluble starch, xylitol and hard materials which do not react with active ingredients such as tea polyphenol, squalene, oleic acid, linoleic acid, linolenic acid, tocopherol, tea saponin, camellia seed protein and the like are used as curing materials, so that the health-care particles for preventing and treating diabetes, hyperglycemia and hypertension have proper solubility, flowability, emulsibility and permeability, and the stability of the product is improved.
Referring to fig. 3, the preparation method of the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension comprises the following steps:
s1, weighing the camellia seed kernel extract, the purslane extract, the dilution filler, the flavoring agent and the lubricant according to the formula amount;
s2, mixing the camellia seed kernel extract and the purslane extract weighed in the step S1, and mechanically stirring for 1 hour to obtain a mixture A; uniformly mixing the diluting filler, the flavoring agent and the lubricant weighed in the step S1 to obtain a mixture B;
s3, adding 50% ethanol into the mixture A obtained in the step S2, carrying out cold soaking extraction for 2 times, filtering, combining filtrates, and concentrating to obtain a thick paste with the relative density of 1.3-1.35 (60 ℃);
s4, adding the mixture B obtained in the step S2 into the thick paste obtained in the step S3, uniformly stirring, spray-drying, crushing, granulating, grading, and performing microwave sterilization to obtain the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension.
Preferably, the mass ratio of the mixture a to the ethanol in the step S3 is 1: 5; the spray drying conditions in step S4 were: the air inlet temperature is 160 ℃, the air outlet temperature is 85 ℃, and the feeding temperature is 45 ℃.
Example 2
A health-care particle for preventing and treating diabetes, hyperglycemia and hypertension comprises the following raw materials by weight: 49g of camellia seed kernel extract, 49g of purslane extract, 500g of dilution filler, 0.8g of flavoring agent and 0.75g of lubricant.
Referring to fig. 1, the preparation method of the camellia seed kernel extract in the present embodiment includes the following steps:
(1) naturally airing or air-drying the mature oil tea fruits, and removing shells and seed shells to obtain oil tea seed kernels;
(2) drying the camellia seed kernels obtained in the step (1) in a dryer until the water content is 12%, and crushing to obtain crushed camellia seed kernels, wherein the particle size of the crushed camellia seed kernels is 20-30 meshes;
(3) sending the camellia seed kernels crushed in the step (2) into a squeezer and squeezing to obtain a crude camellia seed oil product and camellia seed kernel residues;
(4) placing the crude oil-tea camellia seed oil obtained in the step (3) into a plate-and-frame filter press for fine filtration, and degumming, deacidifying, dehydrating, decolorizing, deodorizing and degreasing the crude oil-tea camellia seed oil obtained in the step (3) in the plate-and-frame filter press to obtain refined oil-tea camellia seed oil;
(5) uniformly mixing the tea seed kernel dregs obtained in the step (3) with deionized water, adjusting the pH value to 8-11, adding protease for enzymolysis, wherein the enzymolysis reaction temperature is 45-55 ℃, performing enzymolysis reaction for 1-3 hours, performing centrifugal separation, sequentially obtaining an oil layer, an emulsion layer, a proteolysis liquid layer and a waste liquid layer from top to bottom, sucking layer by layer, and mixing the sucked oil layer and the proteolysis liquid layer to obtain a protein mixed solution; wherein the mass ratio of the tea seed kernel dregs, the deionized water and the protease is 1: 8: 0.85; wherein the protease is alkaline protease;
(6) heating the protein mixed solution obtained in the step (5) to 50 ℃, preserving heat, stirring, adding the refined camellia oleosa seed oil obtained in the step (4), and uniformly stirring and mixing to obtain a solution A; wherein the mass ratio of the refined camellia oleosa seed oil to the protein mixed liquor is 1: 3;
(7) and (4) transferring the solution A obtained in the step (6) into a high-speed shearing emulsifying machine, emulsifying at a high speed for 10min, homogenizing for 2 times in a high-pressure homogenizer, and sterilizing by microwave to obtain the camellia seed kernel extract.
The protease in the embodiment adopts alkaline protease to destroy the cell structure to release the grease, and compared with the grease enzymolyzed by single cellulase or pectinase, the yield is higher, the solubility of a protein system is improved, and the protein content can reach 45%; in addition, through the enzymolysis of protease, protein exists in the form of polypeptide, and is more easily absorbed by human body.
The camellia oleifera fruit stacked for 5-10 years in the embodiment can be adopted as the camellia oleifera fruit, the post-ripening of the camellia oleifera fruit can be promoted and natural fermentation can be carried out simultaneously in the natural air drying process by stacking, part of starch in the camellia oleifera fruit is degraded into carbohydrate with simpler structures such as soluble sugar and the like in the natural fermentation process, the protein is degraded to generate small molecular weight protein, polypeptide and amino acid with higher nutritional value, and the cellulose substance is further degraded under the action of cellulase, so that the extraction speed of the camellia oleifera seed kernel extract is accelerated, the extraction rate is higher, the content of active ingredients in the camellia oleifera seed kernel extract is greatly improved, and the nutritional value is higher.
Referring to fig. 2, the preparation method of the purslane extract in the present embodiment includes the following steps:
a. taking whole purslane as a raw material, cleaning, washing and chopping the whole purslane, putting the cleaned, chopped and chopped whole purslane into an extraction tank, adding deionized water, carrying out ultrasonic treatment for 10min under the conditions of frequency of 30KHz and power of 550W, soaking for 1 hour, decocting for 2.5 hours at 80-95 ℃, and filtering to obtain a first filtrate and a first filter residue; wherein the weight ratio of the fresh purslane to the deionized water is 1: 5;
b. b, putting the first filter residue obtained in the step a into an extraction tank, adding deionized water, carrying out ultrasonic treatment for 10min under the conditions of frequency of 30KHz and power of 550W, soaking for 0.5 h, decocting for 2 h at 80-95 ℃, and filtering to obtain a second filtrate and second filter residue;
c. and (c) combining the first filtrate obtained in the step a and the second filtrate obtained in the step b, and concentrating until the relative density is 1.05-11.10 (60 ℃), so as to obtain the purslane extract.
The purslane whole plant in the embodiment can be the purslane whole plant stacked for 5-10 years, the purslane can be naturally fermented while being naturally air-dried in the stacking process, the unique flavor of the purslane is kept in the natural fermentation process, the bitter taste in the purslane can be thoroughly removed, and meanwhile, the components such as cellulose and hemicellulose which are difficult to absorb and convert by a human body in the purslane are decomposed into small molecular components which can be absorbed by the human body, so that the extraction speed of the purslane extract is higher, the extraction rate is higher, the content of active components in the purslane extract is greatly improved, and the active components in the purslane extract are easier to absorb and digest by the human body.
The diluent filler in this example is a water-soluble starch
The flavoring agent in this example is xylitol.
The lubricant in this example is magnesium stearate.
Referring to fig. 3, the preparation method of the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension comprises the following steps:
s1, weighing the camellia seed kernel extract, the purslane extract, the dilution filler, the flavoring agent and the lubricant according to the formula amount;
s2, mixing the camellia seed kernel extract and the purslane extract weighed in the step S1, and mechanically stirring for 1.5 hours to obtain a mixture A; uniformly mixing the diluting filler, the flavoring agent and the lubricant weighed in the step S1 to obtain a mixture B;
s3, adding 50% ethanol into the mixture A obtained in the step S2, carrying out cold soaking extraction for 3 times, filtering, combining filtrates, and concentrating to obtain a thick paste with the relative density of 1.3-1.35 (60 ℃);
s4, adding the mixture B obtained in the step S2 into the thick paste obtained in the step S3, uniformly stirring, spray-drying, crushing, granulating, grading, and performing microwave sterilization to obtain the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension.
Preferably, the mass ratio of the mixture a to the ethanol in the step S3 is 1: 10; the spray drying conditions in step S4 were: the air inlet temperature is 160 ℃, the air outlet temperature is 85 ℃, and the feeding temperature is 45 ℃.
Example 3
A health-care particle for preventing and treating diabetes, hyperglycemia and hypertension comprises the following raw materials by weight: 45g of camellia seed kernel extract, 20g of purslane extract, 89g of dilution filler, 0.5g of flavoring agent and 0.4g of lubricant.
Referring to fig. 1, the preparation method of the camellia seed kernel extract in the present embodiment includes the following steps:
(1) naturally airing or air-drying the mature oil tea fruits, and removing shells and seed shells to obtain oil tea seed kernels;
(2) drying the camellia seed kernels obtained in the step (1) in a dryer until the water content is 12%, and crushing to obtain crushed camellia seed kernels, wherein the particle size of the crushed camellia seed kernels is 20-30 meshes;
(3) sending the camellia seed kernels crushed in the step (2) into a squeezer and squeezing to obtain a crude camellia seed oil product and camellia seed kernel residues;
(4) placing the crude oil-tea camellia seed oil obtained in the step (3) into a plate-and-frame filter press for fine filtration, and degumming, deacidifying, dehydrating, decolorizing, deodorizing and degreasing the crude oil-tea camellia seed oil obtained in the step (3) in the plate-and-frame filter press to obtain refined oil-tea camellia seed oil;
(5) uniformly mixing the tea seed kernel dregs obtained in the step (3) with deionized water, adjusting the pH value to 8-11, adding protease for enzymolysis, wherein the enzymolysis reaction temperature is 45-55 ℃, performing enzymolysis reaction for 1-3 hours, performing centrifugal separation, sequentially obtaining an oil layer, an emulsion layer, a proteolysis liquid layer and a waste liquid layer from top to bottom, sucking layer by layer, and mixing the sucked oil layer and the proteolysis liquid layer to obtain a protein mixed solution; wherein the mass ratio of the tea seed kernel dregs, the deionized water and the protease is 1: 8: 0.85; wherein the protease is alkaline protease;
(6) heating the protein mixed solution obtained in the step (5) to 50 ℃, preserving heat, stirring, adding the refined camellia oleosa seed oil obtained in the step (4), and uniformly stirring and mixing to obtain a solution A; wherein the mass ratio of the refined camellia oleosa seed oil to the protein mixed liquor is 1: 3;
(7) and (4) transferring the solution A obtained in the step (6) into a high-speed shearing emulsifying machine, emulsifying at a high speed for 10min, homogenizing for 2 times in a high-pressure homogenizer, and sterilizing by microwave to obtain the camellia seed kernel extract.
The protease in the embodiment adopts alkaline protease to destroy the cell structure to release the grease, and compared with the grease enzymolyzed by single cellulase or pectinase, the yield is higher, the solubility of a protein system is improved, and the protein content can reach 45%; in addition, through the enzymolysis of protease, protein exists in the form of polypeptide, and is more easily absorbed by human body.
The camellia oleifera fruit stacked for 5-10 years in the embodiment can be adopted as the camellia oleifera fruit, the post-ripening of the camellia oleifera fruit can be promoted and natural fermentation can be carried out simultaneously in the natural air drying process by stacking, part of starch in the camellia oleifera fruit is degraded into carbohydrate with simpler structures such as soluble sugar and the like in the natural fermentation process, the protein is degraded to generate small molecular weight protein, polypeptide and amino acid with higher nutritional value, and the cellulose substance is further degraded under the action of cellulase, so that the extraction speed of the camellia oleifera seed kernel extract is accelerated, the extraction rate is higher, the content of active ingredients in the camellia oleifera seed kernel extract is greatly improved, and the nutritional value is higher.
Referring to fig. 2, the preparation method of the purslane extract in the present embodiment includes the following steps:
a. taking whole purslane as a raw material, cleaning, washing and chopping the whole purslane, putting the cleaned, chopped and chopped whole purslane into an extraction tank, adding deionized water, carrying out ultrasonic treatment for 10min under the conditions of frequency of 30KHz and power of 550W, soaking for 1 hour, decocting for 2.5 hours at 80-95 ℃, and filtering to obtain a first filtrate and a first filter residue; wherein the weight ratio of the fresh purslane to the deionized water is 1: 5;
b. b, putting the first filter residue obtained in the step a into an extraction tank, adding deionized water, carrying out ultrasonic treatment for 10min under the conditions of frequency of 30KHz and power of 550W, soaking for 0.5 h, decocting for 2 h at 80-95 ℃, and filtering to obtain a second filtrate and second filter residue;
c. and (c) combining the first filtrate obtained in the step a and the second filtrate obtained in the step b, and concentrating until the relative density is 1.05-11.10 (60 ℃), so as to obtain the purslane extract.
The purslane whole plant in the embodiment can be the purslane whole plant stacked for 5-10 years, the purslane can be naturally fermented while being naturally air-dried in the stacking process, the unique flavor of the purslane is kept in the natural fermentation process, the bitter taste in the purslane can be thoroughly removed, and meanwhile, the components such as cellulose and hemicellulose which are difficult to absorb and convert by a human body in the purslane are decomposed into small molecular components which can be absorbed by the human body, so that the extraction speed of the purslane extract is higher, the extraction rate is higher, the content of active components in the purslane extract is greatly improved, and the active components in the purslane extract are easier to absorb and digest by the human body.
The diluent filler in this example is a water-soluble starch
The flavoring agent in this example is xylitol.
The lubricant in this example is magnesium stearate.
Referring to fig. 3, the preparation method of the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension comprises the following steps:
s1, weighing the camellia seed kernel extract, the purslane extract, the dilution filler, the flavoring agent and the lubricant according to the formula amount;
s2, mixing the camellia seed kernel extract and the purslane extract weighed in the step S1, and mechanically stirring for 1.2 hours to obtain a mixture A; uniformly mixing the diluting filler, the flavoring agent and the lubricant weighed in the step S1 to obtain a mixture B;
s3, adding 70% ethanol into the mixture A obtained in the step S2, carrying out cold soaking extraction for 3 times, filtering, combining the filtrates, and concentrating to obtain a thick paste with the relative density of 1.3-1.35 (60 ℃);
s4, adding the mixture B obtained in the step S2 into the thick paste obtained in the step S3, uniformly stirring, spray-drying, crushing, granulating, grading, and performing microwave sterilization to obtain the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension.
Preferably, the mass ratio of the mixture a to the ethanol in the step S3 is 1: 8; the spray drying conditions in step S4 were: the air inlet temperature is 160 ℃, the air outlet temperature is 85 ℃, and the feeding temperature is 45 ℃.
Test example 1
Formulation selection test: in order to ensure the effects of the present invention, the present applicant made a selection of dosage forms.
The health-care particles for preventing and treating diabetes, hyperglycemia and hypertension comprise an oil tea seed extract, a purslane extract, a dilution filler, a flavoring agent and a lubricant, wherein the oil tea seed extract and the purslane extract are combined together on the basis of clinical proved formulas and by combining disease differentiation and syndrome differentiation, the treatment of diabetes needs to be carried out by controlling blood sugar, and the existing diabetes patients can be accompanied with diseases such as hypertension, dyslipidemia, arteriosclerosis and the like. The camellia seed kernel is fruit of camellia oleifera, and the camellia seed kernel extract is extracted from camellia seed kernel. The camellia seed kernel is rich in various nutrient substances such as tea polyphenol, squalene, oleic acid, linoleic acid, linolenic acid, tocopherol and the like, is easy to digest and absorb by human bodies, has the effects of reducing cholesterol, preventing and treating hypertension, cardiovascular diseases and diabetes, and also contains tea saponin and camellia seed protein, wherein the tea saponin is a nonionic surfactant with excellent performance and has physiological activities such as impermeability, inflammation resistance, pain resistance, cancer resistance and the like, and the camellia seed protein consists of 17 amino acids, wherein 7 amino acids such as threonine, phenylalanine, leucine, lysine, tryptophan, valine, isoleucine and the like are necessary for the human bodies. The purslane extract is rich in compounds such as ketones, adrenalins, polysaccharides, various vitamins and amino acids, has the functions of clearing heat, diminishing inflammation, reducing blood fat, reducing blood sugar and resisting atherosclerosis, and can prevent and treat hypertension, cardiovascular diseases, diabetes and liver injury diseases; the curing material is water soluble starch, xylitol and hard materials which do not react with active ingredients such as tea polyphenol, squalene, oleic acid, linoleic acid, linolenic acid, tocopherol, tea saponin, tea seed protein and the like, so that the health-care particles for preventing and treating diabetes, hyperglycemia and hypertension have proper solubility, fluidity, emulsibility and permeability, and the stability of the product is improved; the medicines are used together to play the efficacies of consolidating the constitution, nourishing yin, eliminating turbid pathogen, promoting blood circulation, promoting the production of body fluid and quenching thirst. The granule is convenient for administration and carrying. The preparation has reasonable design, convenient taking and wide application prospect.
Test example 2
Research of a preparation process comprises: in order to ensure the effects of the present invention, the present applicant has studied various parameters in the manufacturing process.
Influence of the amount of ethanol added and the number of cold-extraction times on the yield in step S3.
The test procedure was as follows: weighing the camellia seed kernel extract, the purslane extract, the dilution filler, the flavoring agent and the lubricant according to the formula ratio; mixing the weighed camellia seed kernel extract and the purslane extract, mechanically stirring for 1.2 hours to obtain a mixture A, and uniformly mixing the weighed diluting filler, the flavoring agent and the lubricant to obtain a mixture B; extracting with different ethanol addition amounts and different extraction times, filtering, concentrating the filtrate, and determining the paste yield.
In the present test example, 4 different extraction protocols were set in total, as shown in Table 1.
TABLE 1 different extraction protocols for mixture A
| |
Extracting for 1 time for 1 hr, and adding |
| Scheme | |
| 2 | The extraction is carried out 2 times, each time for 1 hour, and the amount of ethanol added is 6 times of the amount of the |
| Scheme | |
| 3 | The extraction is carried out 2 times, each time for 1 hour, and the amount of ethanol added is 8 times of the amount of the |
| Scheme | |
| 4 | Extracting for 3 times, each for 1 hr, and adding ethanol 8 times the amount of |
| Scheme | |
| 5 | The extraction was carried out 4 times, each for 2 hours, with the amount of ethanol added being 10 times the amount of mixture A each time. |
The effect of different extraction protocols on cream yield is shown in table 2.
TABLE 2 Effect of different extraction protocols of mixture A on cream yield
| Rate of | |
| Scheme | |
| 1 | 23 |
| |
24 |
| |
25.5 |
| |
26 |
| |
25.4 |
As can be seen from tables 1 and 2, the process of extracting mixture a 3 times, each for 1 hour, with the amount of ethanol added being 8 times the amount of mixture a each time, adding 7 times the mass of ethanol to mixture a, cold-soaking for 3 times, filtering, and combining the filtrates is the best in view of energy saving and time cost.
Clinical trial
1. Case collection: the applicant collects 30 patients with diabetes for which diagnosis is confirmed, wherein FPG of the 30 patients with diabetes is 9-10 mmol/L, the FPG is randomly divided into 3 groups, and the data of 10 people in each group and 3 groups of age, disease condition and the like have no significant difference and are comparable.
2. The test method comprises the following steps: the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension prepared in the embodiment 1, the embodiment 2 and the embodiment 3 are respectively taken by 3 groups of patients twice a day, 10mg is taken each time, 7 days is a treatment course, and the test period is three treatment courses.
3. The curative effect standard is as follows: (1) improvement: the blood sugar control level is good and no maladaptive symptoms exist; (2) and (4) invalidation: the diabetes is aggravated or has complications;
4. statistics of treatment outcome
Table 3 statistical table of treatment results.
| Granule for administration | Number of cases | Improvement of life | Invalidation | Adverse reaction | The total effective rate% |
| Example 1 | 10 | 9 | 1 | 0 | 90 |
| Example 2 | 10 | 9 | 1 | 0 | 90 |
| Example 3 | 10 | 10 | 0 | 0 | 100 |
As can be seen from Table 3, in the clinical trial process, patients who use the health-care particles for preventing and treating diabetes, hyperglycemia and hypertension do not find any adverse reaction, and the total effective rate of the health-care particles for preventing and treating diabetes, hyperglycemia and hypertension of the invention on diabetes is more than 90 percent, so that the health-care particles are safe and effective medicines for treating diabetes and have good clinical popularization significance.
Mouse assay
The health-care granules for preventing and treating diabetes, hyperglycemia and hypertension have the hypoglycemic effect on a mouse model by oral administration.
An oral glucose tolerance test was performed on db/db mice (leptin receptor knockout mice) (35 to 39 grams), which are models of type II diabetes. 9 db/db mice were selected and divided into 3 groups of 3 db/db mice per group. 3 db/db mice per group were 1 experimental group and 2 control groups, respectively.
1. Fasting blood glucose levels were measured in db/db mice in an 18 hour gastric emptying fasted state. The health granules for preventing and treating diabetes, hyperglycemia and hypertension, metformin and saline of example 1 were then orally administered to the experimental group and the control group, respectively, by gavage. The dosage of the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension in example 1 is 150mg/Kg of body weight, and the dosage of metformin administered is 300mg/Kg of body weight. Then, each group was administered with 5g/Kg body weight of glucose. Oral Glucose Tolerance Test (OGTT) was performed after 10 minutes, 20 minutes, 40 minutes, 90 minutes, and 120 minutes, respectively. The results are shown in FIG. 4.
2. Fasting blood glucose levels were measured in db/db mice in an 18 hour gastric emptying fasted state. The health granules, metformin and saline of example 2 for the prevention and treatment of diabetes, hyperglycemia and hypertension were then orally administered to the experimental group and the control group, respectively, by gavage. The dosage of the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension in the embodiment 2 is 150mg/Kg of body weight, and the dosage of the metformin to be administered is 300mg/Kg of body weight. Then, each group was administered with 5g/Kg body weight of glucose. Oral Glucose Tolerance Test (OGTT) was performed after 10 minutes, 20 minutes, 40 minutes, 90 minutes, and 120 minutes, respectively. The results are shown in FIG. 5.
3. Fasting blood glucose levels were measured in db/db mice in an 18 hour gastric emptying fasted state. The health granules, metformin and saline of example 3 for the prevention and treatment of diabetes, hyperglycemia and hypertension were then orally administered to the experimental group and the control group, respectively, by gavage. The dosage of the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension in the embodiment 3 is 150mg/Kg of body weight, and the dosage of the metformin to be administered is 300mg/Kg of body weight. Then, each group was administered with 5g/Kg body weight of glucose. Oral Glucose Tolerance Test (OGTT) was performed after 10 minutes, 20 minutes, 40 minutes, 90 minutes, and 120 minutes, respectively. The results are shown in FIG. 6.
As shown in fig. 4, 5 and 6, in the type II diabetic mouse model, the hypoglycemic effect of the health granules of the present invention was confirmed by the oral administration of the health granules of the present invention, which exhibited a hypoglycemic effect in the group to which physiological saline was administered, and such a hypoglycemic effect was also found in the group to which the antidiabetic agent metformin was administered.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (10)
1. A health-care particle for preventing and treating diabetes, hyperglycemia and hypertension is characterized by comprising the following raw materials in parts by weight: 20-80 parts of camellia seed kernel extract, 5-50 parts of purslane extract, 50-600 parts of diluting filler, 0.2-1 part of flavoring agent and 0.3-0.8 part of lubricant.
2. The health-care granules for preventing and treating diabetes, hyperglycemia and hypertension according to claim 1, wherein the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension comprise the following raw materials in parts by weight: 45 parts of camellia seed kernel extract, 20 parts of purslane extract, 89 parts of dilution filler, 0.5 part of flavoring agent and 0.4 part of lubricant.
3. The method for preparing health granules for preventing and treating diabetes, hyperglycemia and hypertension according to claim 1, wherein the method for preparing the camellia seed kernel extract comprises the steps of:
(1) naturally airing or air-drying the mature oil tea fruits, and removing shells and seed shells to obtain oil tea seed kernels;
(2) drying the camellia seed kernels obtained in the step (1) in a dryer until the water content is 10-15%, and crushing to obtain crushed camellia seed kernels, wherein the particle size of the crushed camellia seed kernels is 20-30 meshes;
(3) sending the camellia seed kernels crushed in the step (2) into a squeezer and squeezing to obtain a crude camellia seed oil product and camellia seed kernel residues;
(4) placing the crude oil-tea camellia seed oil obtained in the step (3) into a plate-and-frame filter press for fine filtration, and degumming, deacidifying, dehydrating, decolorizing, deodorizing and degreasing the crude oil-tea camellia seed oil obtained in the step (3) in the plate-and-frame filter press to obtain refined oil-tea camellia seed oil;
(5) uniformly mixing the tea seed kernel dregs obtained in the step (3) with deionized water, adjusting the pH value to 8-11, adding protease for enzymolysis, wherein the enzymolysis reaction temperature is 45-55 ℃, performing enzymolysis reaction for 1-3 hours, performing centrifugal separation, sequentially obtaining an oil layer, an emulsion layer, a proteolysis liquid layer and a waste liquid layer from top to bottom, sucking layer by layer, and mixing the sucked oil layer and the proteolysis liquid layer to obtain a protein mixed solution;
(6) heating the protein mixed solution obtained in the step (5) to 49-53 ℃, preserving heat, stirring, adding the refined camellia oleosa seed oil obtained in the step (4), and uniformly stirring and mixing to obtain a solution A;
(7) and (4) transferring the solution A obtained in the step (6) into a high-speed shearing emulsifying machine, emulsifying at a high speed for 5-30 min, homogenizing for 2 times in a high-pressure homogenizer, and performing microwave sterilization to obtain the camellia seed kernel extract.
4. The method for preparing health granules for preventing and treating diabetes, hyperglycemia and hypertension according to claim 3, wherein the mass ratio of the tea seed kernel dregs, the deionized water and the protease in the step (5) is 1: 5-10: 0.8 to 2.2; the mass ratio of the refined camellia oleosa seed oil to the protein mixed liquor in the step (6) is 1: 2.5 to 4.
5. The health-care particle for preventing and treating diabetes, hyperglycemia and hypertension according to claim 1, wherein the preparation method of the purslane extract comprises the following steps:
a. taking whole purslane as a raw material, cleaning, washing and chopping the whole purslane, putting the cleaned, chopped and chopped whole purslane into an extraction tank, adding deionized water, carrying out ultrasonic treatment for 5-10 min under the conditions of frequency of 20-30 KHz and power of 400-600W, soaking for 1-3 hours, decocting for 2-6 hours at 80-95 ℃, and filtering to obtain a first filtrate and a first filter residue; wherein the weight ratio of the fresh purslane to the deionized water is 1: 2-6;
b. b, putting the first filter residue obtained in the step a into an extraction tank, adding deionized water, carrying out ultrasonic treatment for 5-10 min under the conditions that the frequency is 20-30 KHz and the power is 400-600W, soaking for 0.5-1 h, decocting for 2-4 h at 80-95 ℃, and filtering to obtain a second filtrate and a second filter residue;
c. and (c) combining the first filtrate obtained in the step a and the second filtrate obtained in the step b, and concentrating until the relative density is 1.05-11.10 (60 ℃), so as to obtain the purslane extract.
6. The health granule for preventing and treating diabetes, hyperglycemia and hypertension according to claim 1, wherein the diluent filler is any one or a combination of more of lactose, mannitol, water-soluble starch and water-soluble cyclodextrin.
7. The health granule for preventing and treating diabetes, hyperglycemia and hypertension according to claim 1, wherein the flavoring agent is any one or a combination of more of aspartame, stevioside, xylitol and sodium cyclamate.
8. The health granule for preventing and treating diabetes, hyperglycemia and hypertension according to claim 1, wherein the lubricant is any one or a combination of magnesium stearate, stearic acid, zinc stearate, aerosil and talc.
9. A method for preparing the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension according to any one of claims 1 to 8, comprising the steps of:
s1, weighing the camellia seed kernel extract, the purslane extract, the dilution filler, the flavoring agent and the lubricant according to the formula amount;
s2, mixing the camellia seed kernel extract and the purslane extract weighed in the step S1, and mechanically stirring for 0.5-1.5 hours to obtain a mixture A; uniformly mixing the diluting filler, the flavoring agent and the lubricant weighed in the step S1 to obtain a mixture B;
s3, adding 50-80% ethanol into the mixture A obtained in the step S2, carrying out cold soaking extraction for 2-3 times, filtering, combining filtrates, and concentrating to obtain thick paste with the relative density of 1.3-1.35 (60 ℃);
s4, adding the mixture B obtained in the step S2 into the thick paste obtained in the step S3, uniformly stirring, spray drying, crushing, granulating, grading, and performing microwave sterilization to obtain the health-care granules for preventing and treating diabetes, hyperglycemia and hypertension.
10. The method for preparing health granules for preventing and treating diabetes, hyperglycemia and hypertension according to claim 9, wherein the mass ratio of the mixture a to ethanol in step S3 is 1: 2-10; the spray drying conditions in step S4 are as follows: the air inlet temperature is 160 ℃, the air outlet temperature is 85 ℃, and the feeding temperature is 45 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910801541.7A CN112439012A (en) | 2019-08-28 | 2019-08-28 | Health-care granules for preventing and treating diabetes, hyperglycemia and hypertension and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910801541.7A CN112439012A (en) | 2019-08-28 | 2019-08-28 | Health-care granules for preventing and treating diabetes, hyperglycemia and hypertension and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112439012A true CN112439012A (en) | 2021-03-05 |
Family
ID=74741056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910801541.7A Pending CN112439012A (en) | 2019-08-28 | 2019-08-28 | Health-care granules for preventing and treating diabetes, hyperglycemia and hypertension and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112439012A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709337A (en) * | 2005-06-21 | 2005-12-21 | 蒋伟哲 | Tea-seed oil soft capsule formulation |
| CN102838682A (en) * | 2011-06-22 | 2012-12-26 | 吴梦云 | Extraction process of polysaccharide in purslane |
| CN103820214A (en) * | 2014-03-11 | 2014-05-28 | 安徽亿宏生物科技有限公司 | Tea oil squeezing method |
| CN104974847A (en) * | 2015-06-09 | 2015-10-14 | 武汉轻工大学 | Aqueous enzymatic method for simultaneous preparation of camellia seed oil and camellia seed protein |
| CN106262890A (en) * | 2016-08-12 | 2017-01-04 | 贵州省玉屏县金心笛油脂开发有限公司 | A kind of tea oil health-care product with hypolipemic function and preparation method thereof |
| CN110200276A (en) * | 2019-06-27 | 2019-09-06 | 刘东波 | Composition and the application for being used to treat diabetes based on Chinese medicine nutrition treatment |
-
2019
- 2019-08-28 CN CN201910801541.7A patent/CN112439012A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709337A (en) * | 2005-06-21 | 2005-12-21 | 蒋伟哲 | Tea-seed oil soft capsule formulation |
| CN102838682A (en) * | 2011-06-22 | 2012-12-26 | 吴梦云 | Extraction process of polysaccharide in purslane |
| CN103820214A (en) * | 2014-03-11 | 2014-05-28 | 安徽亿宏生物科技有限公司 | Tea oil squeezing method |
| CN104974847A (en) * | 2015-06-09 | 2015-10-14 | 武汉轻工大学 | Aqueous enzymatic method for simultaneous preparation of camellia seed oil and camellia seed protein |
| CN106262890A (en) * | 2016-08-12 | 2017-01-04 | 贵州省玉屏县金心笛油脂开发有限公司 | A kind of tea oil health-care product with hypolipemic function and preparation method thereof |
| CN110200276A (en) * | 2019-06-27 | 2019-09-06 | 刘东波 | Composition and the application for being used to treat diabetes based on Chinese medicine nutrition treatment |
Non-Patent Citations (3)
| Title |
|---|
| 范少丽，等: "马齿苋全草油的亚临界流体萃取、脂肪酸分析及抗氧化活性", 《食品与发酵工业》 * |
| 高红梅，等: "马齿苋降血糖有效部位研究", 《长春中医药大学学报》 * |
| 黄翠莉，等: "油茶籽油对大鼠降血脂和预防脂肪肝的影响", 《食品科学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2345416B1 (en) | Pharmaceutical composition for purifing vein and preparation method thereof | |
| CN108186690A (en) | A kind of Chinese medicine processing method | |
| CN103689296A (en) | Feed for ewe at later pregnancy and lactation period and preparation method thereof | |
| CN106177339A (en) | A kind of method preparing treatment gout herbal formulation | |
| CN101133837B (en) | Chickpea nutrition powder and method for preparing the same | |
| CN106108031A (en) | Garlic skin dietary fiber and high temperature steaming thereof and enzymolysis modified technology of preparing and application | |
| TWI763970B (en) | Carob fruit composition and preparation method and application thereof | |
| CN108936178A (en) | It is a kind of for preventing and treating the solid beverage and preparation method thereof of dysmenorrhea and gynaecological imflammation | |
| KR101402852B1 (en) | Fermented bellflower pills and Preparation thereof | |
| CN112439012A (en) | Health-care granules for preventing and treating diabetes, hyperglycemia and hypertension and preparation method thereof | |
| JP2008503542A (en) | Plant-derived product containing proanthocyanidins and process for producing the same | |
| CN106387904A (en) | Composition, preparation method of composition, preparation and use | |
| CN107375697B (en) | Compound preparation with bowel relaxing function and preparation method and application thereof | |
| KR101093006B1 (en) | Method for producing functional health food containing bezoar bovis used microbes and the functional health food produced by the same | |
| CN106617038B (en) | Health food composition for improving male frequent micturition and urinary incontinence and preparation method and application thereof | |
| CN110051598A (en) | A kind of pet skin care cleaning solution and preparation method thereof | |
| CN112957386B (en) | Processing method of traditional Chinese medicine decoction pieces | |
| CN111773263A (en) | Pharmaceutical composition for treating kidney cancer and preparation method thereof | |
| CN115040572B (en) | Natural composition for promoting oil discharge and reducing weight and preparation method thereof | |
| CN110170027B (en) | Hawthorn and monascus powder pills and preparation method thereof | |
| CN108477460A (en) | A kind of composition and preparation method thereof having effect of relaxing bowel | |
| CN106819252A (en) | Reducing blood lipid beauty tea and preparation method thereof | |
| CN1298377C (en) | Wheat seeding powder for preventing and treating insulin resisting syndrome and its preparation process | |
| CN105053915B (en) | A kind of sweet potato health care product and preparation method thereof | |
| CN117898388A (en) | Solid beverage and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210305 |
|
| RJ01 | Rejection of invention patent application after publication |